Dendright has developed a platform vaccine technology based on Dendritic Cells to treat autoimmune diseases such as Rheumatoid Arthritis, Type 1 Diabetes and Multiple Sclerosis. The technology utilises the body’s own immune system to “silence” those T cells that cause these severe chronic diseases. The technology can also be applicable to symptoms associated with allergy, transplantation, and graft rejection.